ZeoSys Medical

ZeoSys Medical is a German medical-technology company focused on making volatile anaesthesia more sustainable and more economical. According to its official website, its innovative systems help hospitals, anaesthesiology practices, veterinary practitioners and farmers reduce the environmental and cost burden of volatile anaesthetics. The company positions itself around a holistic approach that combines effective medical treatment with the reduction of greenhouse-gas emissions and clear cost-saving potential for healthcare providers. The company's best-known achievement is in anaesthetic gas recovery. ZeoSys Medical states that it became the first company worldwide to obtain regulatory approval for the recovery of the finished drug sevoflurane, a volatile anaesthetic used globally. In June 2024 it entered the market with Sevofluran Zeosys 100% in Austria. This makes the company a specialist not only in anaesthesia technology but also in the circular use of anaesthetic agents. Beyond human medicine, ZeoSys Medical serves veterinary medicine and agriculture. Since 1 January 2021, anaesthesia has been mandatory for piglet castration in Germany, and the company supplies a filter system intended to support animal welfare and a safe, clean piglet anaesthesia process. This reflects the company's broader mission of protecting people and the environment. ZeoSys Medical describes itself as innovative anaesthesiology technology from Brandenburg for the whole world. Since 2019 it has conducted research and production at the Biotechnology Park Luckenwalde, about 50 km south of Berlin. It covers international demand through renowned and strong partners, while marketing and distributing its products independently in German-speaking countries. Wikidata lists the company as being in Apolda, Germany, which may reflect an earlier or registered location; the official website identifies Luckenwalde as its research and production base.

ZeoSys Medical is a German medical-technology company that has been researching and producing at the Biotechnology Park Luckenwalde in Brandenburg since 2019. The location, about 50 km south of Berlin, serves as its research and production base. The company describes itself as developing innovative anaesthesiology technology from Brandenburg for the whole world, covering international demand through renowned and strong partners while marketing and distributing its products independently in German-speaking countries. The company's central focus is volatile anaesthesia, a widely used form of anaesthesia based on inhaled agents such as sevoflurane. Volatile anaesthetics are effective in clinical practice but are also potent greenhouse gases when released into the atmosphere, and they represent a significant cost factor for hospitals and anaesthesiology practices. ZeoSys Medical's systems are designed to address both issues by reducing emissions and lowering costs. A major milestone came when ZeoSys Medical became the first company worldwide to obtain regulatory approval for the recovery of the finished drug sevoflurane. This approval allowed the company to recover and reuse a volatile anaesthetic that is used globally, an approach that supports both environmental and economic goals. In June 2024, the company achieved market entry for Sevofluran Zeosys 100% in Austria, marking an important commercial step for its recovery-based product line. ZeoSys Medical also expanded its activities into veterinary medicine and agriculture. Since 1 January 2021, German regulations have required anaesthesia for piglet castration. The company supplies a filter system for this application, contributing to animal welfare and enabling a safe and clean piglet anaesthesia process. This veterinary line complements its human-medicine offerings and reflects the company's stated mission of protecting people and the environment. Wikidata records the company as being located in Apolda, Germany, which may reflect a registered or earlier address, while the official website identifies Luckenwalde as the site of research and production. The company remains privately held and active, with a focus on sustainable medical-technology innovation.

• 2024

  Market entry of Sevofluran Zeosys 100% in Austria in June.

• 2021

  Anaesthesia becomes mandatory for piglet castration in Germany on 1 January; ZeoSys Medical supplies a filter system for this application.

• 2019

  ZeoSys Medical begins research and production at the Biotechnology Park Luckenwalde in Brandenburg.

Sustainable, innovative anaesthesiology technology from Brandenburg for global markets, combining environmental protection with cost savings for healthcare providers.

• Sevoflurane recovery system

  System enabling the recovery of the finished drug sevoflurane, for which ZeoSys Medical obtained the world's first regulatory approval.

• Sevofluran Zeosys 100%

  Recovered sevoflurane product that entered the Austrian market in June 2024.

• Filter system for piglet anaesthesia

  Filter system supporting safe and clean piglet anaesthesia, contributing to animal welfare.

1. 1ZeoSys Medical GmbH - Wir machen den Anästhesieprozess nachhaltigzeosys-medical.de
2. 2ZeoSys Medical (Germany) - Wikidatawikidata.org